Platelet-Rich Plasma (PRP) remains a topic of controversy in Sports Medicine. One of the limitations surrounding this therapy is the paucity of high-quality data to support or refute its efficacy. We welcome Dr. Dean Wang, MD from UC Irvine to discuss his study looking at the fragility of the highest quality data we have on PRP. A fragile study is one in which the study’s conclusion would change with the reversal of only a few outcomes. Our medical community holds randomized-controlled trials in high regard, however if these studies are fragile, how much can we rely on them to be true?